Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis

Cell Cycle

Volumn 13, Issue 12, 2014, Pages 1958-1969

  Bao, Ying Na ^a,b   Cao, Xue ^a   Luo, Dong Hua ^a   Sun, Rui ^a   Peng, Li Xia ^a   Wang, Lin ^a   Yan, Yong Pan ^c   Zheng, Li Sheng ^a   Xie, Ping ^a   Cao, Yun ^a   Liang, Ying Ying ^a   Zheng, Fang Jing ^a   Huang, Bi Jun ^a   Xiang, Yan Qun ^a   Lv, Xing ^a   Chen, Qiu Yan ^a   Chen, Ming Yuan ^a   Huang, Pei Yu ^a   Guo, Ling ^a   Mai, Hai Qiang ^a   Guo, Xiang ^a   Zeng, Yi Xin ^a   Qian, Chao Nan ^a   more..

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b INNER MONGOLIA MEDICAL UNIVERSITY   (China)

^c Gencode Technologies   (United States)

Author keywords

Genome wide expression profiling; JAK; Metastasis; Nasopharyngeal carcinoma; STAT; Tumor growth; uPAR

Indexed keywords

JANUS KINASE 2; JANUS KINASE 3; NERVE CELL ADHESION MOLECULE; PLASMIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; UROKINASE RECEPTOR; UVOMORULIN; VIMENTIN; ENZYME INHIBITOR; JANUS KINASE; PYRAZOLE DERIVATIVE; RUXOLITINIB; STAT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; COLONY FORMATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; METASTASIS; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION; ADOLESCENT; ADULT; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; MALE; METABOLISM; MIDDLE AGED; MOUSE; NASOPHARYNX TUMOR; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; XENOGRAFT;

ADOLESCENT; ADULT; AGED; ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; ENZYME INHIBITORS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HETEROGRAFTS; HUMANS; JANUS KINASES; MALE; MICE; MICE, NUDE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; PYRAZOLES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84902440808     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.28921     Document Type: Article

References (52)

1. Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer 2011; 30:114-9; PMID:21272443; http://dx.doi.org/10.5732/cjc.010.10377
2. Kataki AC, Simons MJ, Das AK, Sharma K, Mehra NK. Nasopharyngeal carcinoma in the Northeastern states of India. Chin J Cancer 2011; 30:106-13; PMID:21272442; http://dx.doi.org/10.5732/cjc.010.10607
3. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, Tan IB, Middeldorp JM. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer 2012; 31:185-96; PMID:22313595; http://dx.doi.org/10.5732/cjc.011.10328
4. Sarmiento MP, Mejia MB. Preliminary assessment of nasopharyngeal carcinoma incidence in the Philippines: a second look at published data from four centers. Chin J Cancer 2014; 33:159-64; PMID:23958058
5. Ahmad A, Stefani S. Distant metastases of nasopharyngeal carcinoma: a study of 256 male patients. J Surg Oncol 1986; 33:194-7; PMID:3773537; http://dx.doi.org/10.1002/jso.2930330310
6. Lee AW, Poon YF, Foo W, Law SC, Cheung FK, Chan DK, Tung SY, Thaw M, Ho JH. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992; 23:261-70; PMID:1587745; http://dx.doi.org/10.1016/0360- 3016(92)90740-9
7. Hsu MM, Tu SM. Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy. Cancer 1983; 52:362-8; PMID:6190547; http://dx.doi.org/10.1002/1097-0142(19830715)52:2〈362:: AIDCNCR2820520230〉3.0.CO;2-V
8. Huang CJ, Leung SW, Lian SL, Wang CJ, Fang FM, Ho YH. Patterns of distant metastases in nasopharyngeal carcinoma. Kaohsiung J Med Sci 1996; 12:229-34; PMID:8683644
9. Wei WI, Mok VW. The management of neck metastases in nasopharyngeal cancer. Curr Opin Otolaryngol Head Neck Surg 2007; 15:99-102; PMID:17413410; http://dx.doi.org/10.1097/MOO.0b013e3280148a06
10. Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT, Zee BC, Law SC, Teo PM, Tung SY, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2005; 61:1107-16; PMID:15752890; http://dx.doi.org/10.1016/j.ijrobp.2004.07.702
11. Ploug M, Rønne E, Behrendt N, Jensen AL, Blasi F, Danø K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991; 266:1926-33; PMID:1846368
12. Ploug M, Ellis V. Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett 1994; 349:163-8; PMID:8050560; http://dx.doi.org/10.1016/0014-5793(94)00674-1
13. Kjaergaard M, Hansen LV, Jacobsen B, Gardsvoll H, Ploug M. Structure and ligand interactions of the urokinase receptor (uPAR). Front Biosci 2008; 13:5441-61; PMID:18508598; http://dx.doi.org/10.2741/3092
14. Ellis V, Pyke C, Eriksen J, Solberg H, Danø K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann N Y Acad Sci 1992; 667:13-31; PMID:1339241; http://dx.doi.org/10.1111/j.1749-6632. 1992.tb51591.x
15. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaître V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997; 17:439-44; PMID:9398846; http://dx.doi.org/10.1038/ng1297-439
16. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3:932-43; PMID:12461559; http://dx.doi.org/10.1038/nrm977
17. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010; 11:23-36; PMID:20027185; http://dx.doi.org/10.1038/nrm2821
18. Jacobsen B, Ploug M. The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition. Curr Med Chem 2008; 15:2559-73; PMID:18855679; http://dx.doi.org/10.2174/ 092986708785909012
19. Rasch MG, Lund IK, Almasi CE, Hoyer-Hansen G. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front Biosci 2008; 13:6752-62; PMID:18508692; http://dx.doi.org/10.2741/3186
20. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012; 36:503-14; PMID:22520844; http://dx.doi.org/10.1016/j.immuni.2012.03.013
21. Harrison DA. The Jak/STAT pathway. Cold Spring Harb Perspect Biol 2012; 4; PMID:22383755; http://dx.doi.org/10.1101/cshperspect.a011205
22. Vera J, Rateitschak K, Lange F, Kossow C, Wolkenhauer O, Jaster R. Systems biology of JAK-STAT signalling in human malignancies. Prog Biophys Mol Biol 2011; 106:426-34; PMID:21762720; http://dx.doi.org/10.1016/j.pbiomolbio. 2011.06.013
23. Dumler I, Weis A, Mayboroda OA, Maasch C, Jerke U, Haller H, Gulba DC. The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem 1998; 273:315-21; PMID:9417082; http://dx.doi.org/10.1074/jbc.273.1.315
24. Koshelnick Y, Ehart M, Hufnagl P, Heinrich PC, Binder BR. Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J Biol Chem 1997; 272:28563-7; PMID:9353320; http://dx.doi.org/10.1074/jbc.272.45.28563
25. Nusrat AR, Chapman HA Jr. An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J Clin Invest 1991; 87:1091-7; PMID:1847936; http://dx.doi.org/10.1172/JCI115070
26. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269:32380-8; PMID:7528215
27. Kjøller L, Hall A. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol 2001; 152:1145-57; PMID:11257116; http://dx.doi.org/10.1083/jcb.152.6.1145
28. Madsen CD, Ferraris GM, Andolfo A, Cunningham O, Sidenius N. uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol 2007; 177:927-39; PMID:17548516; http://dx.doi.org/10.1083/jcb.200612058
29. Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010; 584:1923-30; PMID:20036661; http://dx.doi.org/10.1016/j.febslet.2009.12.039
30. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139:871-90; PMID:19945376; http://dx.doi.org/10.1016/j.cell.2009.11.007
31. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119:1420-8; PMID:19487818; http://dx.doi.org/10.1172/ JCI39104
32. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009; 119:1429-37; PMID:19487819; http://dx.doi.org/10.1172/JCI36183
33. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000; 12:613-20; PMID:10978898; http://dx.doi.org/10.1016/ S0955-0674(00)00140-X
34. Liu D, Aguirre Ghiso J, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002; 1:445-57; PMID:12124174; http://dx.doi.org/10.1016/S1535-6108(02)00072-7
35. Gondi CS, Kandhukuri N, Dinh DH, Gujrati M, Rao JS. Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. Int J Oncol 2007; 31:19-27; PMID:17549401
36. Lester RD, Jo M, Montel V, Takimoto S, Gonias SL. uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol 2007; 178:425-36; PMID:17664334; http://dx.doi.org/10.1083/jcb.200701092
37. Nguyen DH, Webb DJ, Catling AD, Song Q, Dhakephalkar A, Weber MJ, Ravichandran KS, Gonias SL. Urokinase-type plasminogen activator stimulates the Ras/Extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells. J Biol Chem 2000; 275:19382-8; PMID:10777511; http://dx.doi.org/10.1074/jbc.M909575199
38. Smith HW, Marra P, Marshall CJ. uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180. J Cell Biol 2008; 182:777-90; PMID:18725541; http://dx.doi.org/10.1083/jcb.200712050
39. Jo M, Lester RD, Montel V, Eastman B, Takimoto S, Gonias SL. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem 2009; 284:22825-33; PMID:19546228; http://dx.doi.org/10.1074/jbc.M109. 023960
40. Gupta R, Chetty C, Bhoopathi P, Lakka S, Mohanam S, Rao JS, Dinh DE. Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelialmesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells. Int J Oncol 2011; 38:733-44; PMID:21181094
41. Mazar AP. The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anticancer Drugs 2001; 12:387-400; PMID:11395568; http://dx.doi.org/10.1097/00001813-200106000-00001
42. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003; 22:205-22; PMID:12784997; http://dx.doi.org/10.1023/A: 1023099415940
43. Li Y, Cozzi PJ. Targeting uPA/uPAR in prostate cancer. Cancer Treat Rev 2007; 33:521-7; PMID:17658220; http://dx.doi.org/10.1016/j.ctrv.2007.06.003
44. Baldini E, Sorrenti S, D'Armiento E, Di Matteo FM, Catania A, Ulisse S. The urokinase plasminogen activating system in thyroid cancer: clinical implications. G Chir 2012; 33:305-10; PMID:23095556
45. LeBeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, VanBrocklin HF, Craik CS. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res 2013; 73:2070-81; PMID:23400595; http://dx.doi.org/10.1158/0008-5472.CAN-12-3526
46. Qian CN, Berghuis B, Tsarfaty G, Bruch M, Kort EJ, Ditlev J, Tsarfaty I, Hudson E, Jackson DG, Petillo D, et al. Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res 2006; 66:10365-76; PMID:17062557; http://dx.doi.org/10.1158/0008-5472.CAN-06-2977
47. Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, Peng LX, Lu WH, Zhang Z, Petillo D, et al. Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res 2011; 71:3162-72; PMID:21289131; http://dx.doi.org/10.1158/0008-5472.CAN-10-3557
48. Song LB, Yan J, Jian SW, Zhang L, Li MZ, Li D, Wang HM. [Molecular mechanisms of tumorgenesis and metastasis in nasopharyngeal carcinoma cell sublines]. Ai Zheng 2002; 21:158-62; PMID:12479066
49. Li XJ, Peng LX, Shao JY, Lu WH, Zhang JX, Chen S, Chen ZY, Xiang YQ, Bao YN, Zheng FJ, et al. As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelial-mesenchymal transition and activation of AKT signaling. Carcinogenesis 2012; 33:1302-9; PMID:22610073; http://dx.doi.org/10.1093/carcin/ bgs181
50. Liang Y, Zhong Z, Huang Y, Deng W, Cao J, Tsao G, Liu Q, Pei D, Kang T, Zeng YX. Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. J Biol Chem 2010; 285:4931-40; PMID:20007324; http://dx.doi.org/10.1074/jbc.M109.048397
51. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24:148-54; PMID:2544306; http://dx.doi.org/10.1007/BF00300234
52. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410:50-6; PMID:11242036; http://dx.doi.org/10.1038/35065016